FiercePharma  Jun 18  Comment 
Inspire Pharmaceuticals' AzaSite is approved to treat bacterial conjunctivitis, more commonly known as pink eye. But that's not all the company hawked it for when it was part of Merck & Co., the U.S. Justice Department says.
Stock Wizard  Apr 5  Comment 
Below we highlight few companies whose shares are actively trading in Tuesday's session. Shares of American International Group (NYSE: AIG) jumped as much 4% on Tuesday after Chief Executive Bob Benmosche said tha the bailed-out insurer is...
TheStreet.com  Apr 5  Comment 
NEW YORK (TheStreet) -- Merck plans to acquire Inspire Pharmaceuticals for about $430 million. Merck will buy Inspire at $5 a share in cash, representing a 26% premium to Inspire's closing price on Monday of $3.98. Inspire shares were...
MarketWatch  Feb 17  Comment 
Inspire and AVEO are the lead gainers in drug stocks trading on Thursday.
StreetInsider.com  Feb 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Inspire+Pharma+%28ISPH%29+Reducing+Workforce+by+27%25+to+Focus+on+Eye+Care+Business/6304726.html for the full story.
StreetInsider.com  Jan 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Madison+Williams+Upgrades+Inspire+Pharma+%28ISPH%29+to+Buy/6222500.html for the full story.
Penny Stock DD  Jan 5  Comment 
Repros Therapeutics Inc. (NASDAQ:RPRX) gained by 3.78% to close at $3.02 with overall traded volume of 1.34 million shares in the last trading session. The share price is likely to move by 0.34 times against 1 point change in market index. The...
MarketWatch  Jan 3  Comment 
Shares of Inspire Pharmaceuticals are tanking on a failed late-stage study for its cystic fibrosis drug denufosol.
MarketWatch  Jan 3  Comment 
Inspire Pharmaceuticals shares were crushed in premarket trading Monday after the biotech group reported that a Phase III clinical trial for its drug denufosol failed to show it was effective in treating cystic fibrosis. Inspire shares were down...
StreetInsider.com  Jan 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Inspire+Pharma+%28ISPH%29+TIGER-2+Top-Line+Results+of+TIGER-2+Not+Statistically+Significant/6187814.html for the full story.


Durham, N.C. based Inspire Pharmaceuticals, Inc. (ISPH) is a specialty pharmaceutical company engaged in the development and commercialization of treatments for Respiratory and Ophthalmologic Disorders. Currently, ISPH has Food & Drug Administration (FDA) approval for three products: Elestat for allergic conjunctivitis, Restasis for dry eye disease and AzaSite (1.0% azithromycin ophthalmic solution) for bacterial conjunctivitis. Elestat and Restasis were launched in the U.S. in February 2004 and April 2003, respectively, with marketing partner Allergan Pharmaceuticals. Elestat continues to hold the position of the second most prescribed allergic conjunctivitis product in the U.S. market. In February 2007, Inspire licensed AzaSite (1.0% azithromycin ophthalmic solution) from InSite Vision Incorporated for the US and Canadian commercialization. AzaSite was approved by the FDA in April 2007 for the treatment of bacterial conjunctivitis and Inspire launched AzaSite in middle August 2007.

Inspire is also developing advanced products for ophthalmologic disorders with Allergan, the lead candidate being INS365 (Prolacria). The company has several collaborative agreements, and selectively retains commercializing and marketing rights in them. Its leading pipeline candidate is Denufosol for cystic fibrosis (phase III). Inspire recently added another candidate to its pipeline an intranasal dosage form of epinastine (phase II) for the treatment or prevention of rhinitis. In November, 2006, Inspire and FAES Farma, S.A. signed a licensing agreement for the U.S. and Canadian development and commercialization of Bilastine, a phase III oral antihistamine compound for the treatment or prevention of allergic rhinitis.

Inspire generates revenue through profit splitting and royalty payments on its ophthalmologic disorder products Restasis and Elestat with Allergan. It also receives payments for the achievement of contractual milestones by its collaboration partners, which are recognized over the remaining period of its research and development (R&D) commitments under the relevant contracts. From the third quarter of 2007, we believe AzaSite should make a meaningful contribution to the company's top line. The company employs roughly 200 professionals.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki